Akero Therapeutics Q2 and Business Update
Akero Therapeutics (AKRO) reported second-quarter financial results for the period ending June 30, 2024, and provided business updates.
From Akero Therapeutics
Andrew Cheng, president and CEO said, “The second quarter of 2024 brought important progress for EFX with the initiation of the . . .
This content is for paid subscribers.
Today’s Highlights
August 9, 2024
